Humacyte, Inc. (HUMA)Healthcare | Biotechnology | Durham, United States | NasdaqGS
0.69 USD
0.00
(-0.360%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:49 a.m. EDT
The fundamental reality here is stark: Humacyte is a cash-burning biotech company with no revenue growth (-4.3%), negative returns on equity, and a balance sheet that is barely covering its obligations. The stock has lost nearly 77% of its value over the last four years, and the most recent annual performance was another severe decline. While the price-to-book ratio looks cheap at 13x, this is a classic value trap; the book value is eroding due to losses, not a hidden asset base. The recent news of institutional investors increasing stakes is likely a hedge against a binary outcome rather than a vote of confidence in the current trajectory. Short-term, the stock is trapped in a downtrend, trading well below its 50-day and 200-day averages, with no immediate catalyst to reverse this momentum. The options market is pricing in a 'lottery ticket' scenario where a single positive event could send the price soaring, but the probability of that happening soon is low given the lack of commercialization progress. Long-term, the investment case relies entirely on a future breakthrough that hasn't happened yet. Until there is sustained revenue growth and a path to profitability, this remains a high-risk speculative vehicle unsuitable for capital preservation. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.345379 |
| AutoETS | 0.345382 |
| MSTL | 0.346213 |
| AutoTheta | 0.600517 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 5.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.526 |
| Excess Kurtosis | -0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 572.101 |
| Revenue per Share | 0.012 |
| Market Cap | 186,373,888 |
| Forward P/E | -2.88 |
| Beta | 2.52 |
| Website | https://www.humacyte.com |
As of July 11, 2026, 3:49 a.m. EDT: Options activity reveals a distinct 'long gamma' setup where traders are betting on continued volatility rather than a specific directional move. Call Open Interest is heavily concentrated at strikes significantly above the current price ($1.50, $2.00, $3.50), while Put Open Interest is clustered just above the current price ($1.00, $1.50). This structure suggests speculators are positioning for a binary event—likely a clinical trial result or regulatory decision—that could cause the stock to gap up to the call strikes or gap down to the put strikes, rather than expecting a steady grind higher. The massive disparity in volume and open interest between calls and puts indicates a speculative bias toward upside potential, despite the current downtrend.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.71902835 |
| Address1 | 2,525 East North Carolina Highway 54 |
| All Time High | 17.45 |
| All Time Low | 0.547 |
| Ask | 0.8869 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 17,650,350 |
| Average Daily Volume3 Month | 10,463,724 |
| Average Volume | 10,463,724 |
| Average Volume10Days | 17,650,350 |
| Beta | 2.517 |
| Bid | 0.49 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.052 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6912 |
| Current Ratio | 3.929 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.7099 |
| Day Low | 0.68 |
| Debt To Equity | 572.101 |
| Display Name | Humacyte |
| Earnings Call Timestamp End | 1,778,673,600 |
| Earnings Call Timestamp Start | 1,778,673,600 |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,365,000 |
| Earnings Timestamp Start | 1,786,365,000 |
| Ebitda | -105,185,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.63 |
| Enterprise To Revenue | 85.031 |
| Enterprise Value | 171,421,600 |
| Eps Current Year | -0.35 |
| Eps Forward | -0.24 |
| Eps Trailing Twelve Months | -0.63 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.99004 |
| Fifty Day Average Change | -0.29884 |
| Fifty Day Average Change Percent | -0.30184639 |
| Fifty Two Week Change Percent | -71.90283 |
| Fifty Two Week High | 2.84 |
| Fifty Two Week High Change | -2.1488 |
| Fifty Two Week High Change Percent | -0.7566197 |
| Fifty Two Week Low | 0.547 |
| Fifty Two Week Low Change | 0.14420003 |
| Fifty Two Week Low Change Percent | 0.2636198 |
| Fifty Two Week Range | 0.547 - 2.84 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,606,833,000,000 |
| Float Shares | 196,127,240 |
| Forward Eps | -0.24 |
| Forward P E | -2.88 |
| Free Cashflow | -64,806,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 184 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -81,723,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07506 |
| Held Percent Institutions | 0.22275999 |
| Implied Shares Outstanding | 269,638,156 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina. |
| Long Name | Humacyte, Inc. |
| Market | us_market |
| Market Cap | 186,373,888 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_107706507 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -95,217,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 186,373,893 |
| Number Of Analyst Opinions | 5 |
| Open | 0.691 |
| Operating Cashflow | -101,545,000 |
| Operating Margins | -57.0404 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 919 313 9633 |
| Pre Market Change | -0.01670003 |
| Pre Market Change Percent | -2.4160922 |
| Pre Market Price | 0.6745 |
| Pre Market Time | 1,784,022,489 |
| Previous Close | 0.6937 |
| Price Eps Current Year | -1.9748572 |
| Price Hint | 4 |
| Price To Book | 13.292308 |
| Price To Sales Trailing12 Months | 92.447365 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.025 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0025 |
| Regular Market Change Percent | -0.360386 |
| Regular Market Day High | 0.7099 |
| Regular Market Day Low | 0.68 |
| Regular Market Day Range | 0.68 - 0.7099 |
| Regular Market Open | 0.691 |
| Regular Market Previous Close | 0.6937 |
| Regular Market Price | 0.6912 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 7,536,058 |
| Return On Assets | -0.51485 |
| Return On Equity | -4.0947 |
| Revenue Growth | -0.043 |
| Revenue Per Share | 0.012 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 269,638,156 |
| Shares Percent Shares Out | 0.1172 |
| Shares Short | 31,597,133 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 40,140,620 |
| Short Name | Humacyte, Inc. |
| Short Percent Of Float | 0.1179 |
| Short Ratio | 1.87 |
| Source Interval | 15 |
| State | NC |
| Symbol | HUMA |
| Target High Price | 4.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 2.05 |
| Target Median Price | 2.0 |
| Total Cash | 48,539,000 |
| Total Cash Per Share | 0.219 |
| Total Debt | 66,501,000 |
| Total Revenue | 2,016,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.63 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.133635 |
| Two Hundred Day Average Change | -0.44243503 |
| Two Hundred Day Average Change Percent | -0.39027995 |
| Type Disp | Equity |
| Volume | 7,536,058 |
| Website | https://www.humacyte.com |
| Zip | 27,713 |